Isrea D Capsule SR is a combination pharmaceutical formulation containing Domperidone 30 mg and Esomeprazole 40 mg, designed for the management of gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and gastric discomfort. Esomeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, providing effective relief from acid-related conditions including gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The sustained-release (SR) formulation ensures prolonged therapeutic plasma concentrations, enhancing efficacy and patient compliance by reducing dosing frequency. Isrea D Capsule SR is indicated for patients requiring combined prokinetic and acid suppression therapy, particularly in cases of reflux esophagitis with delayed gastric emptying or functional dyspepsia. It should be used under medical supervision, considering contraindications such as hypersensitivity to components, prolactinoma, or concurrent medications that may interact adversely. Common side effects may include headache, dry mouth, abdominal cramps, or dizziness. Proper adherence to prescribed dosage and monitoring is essential to optimize therapeutic outcomes and minimize adverse effects.